Extreme Drug Resistance for Multiple Myeloma
Learn More About Multiple Myeloma Extreme Drug Resistance: Chat with Us | Email Us
Multiple Myeloma: Extreme Drug Resistance
Before proceeding with a chemotherapy regimen to treat multiple myeloma, it is important to first ascertain how effective the treatment is likely to be. One of the innovative ways we accomplish this at Cancer Treatment Centers of America (CTCA) hospitals is by using the Extreme Drug Resistance (EDR) Assay (or chemoresistance).
Designed for testing solid tumors, the EDR is a highly accurate test which gauges how resistant a tumor is likely to be to specific chemotherapeutic drugs. If the abnormal plasma cells (myeloma cells) continue to grow after extreme exposure to a chemotherapy drug, this indicates the presence of significant drug resistance. Therefore, if the tumor is resistant that particular drug, then the tumor growing in a patient’s body is also likely to be resistant.
This information allows CTCA oncologists to customize multiple myeloma treatment to your unique needs, helping to avoid toxicity and minimize costs.
Next Topic: MRI for Multiple Myeloma
